Who are UGN-103's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CHS-0214, BMS-986353, KITE-753, AK120, Placebo+AK111, Pf-08052666.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ugn-103.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

UGN-103 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UGN-103 (UGN-103) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule. Area: Oncology.

phase 3 Small molecule Not publicly disclosed Oncology Small molecule Live · refreshed every 30 min

Target snapshot

UGN-103 (UGN-103) — UroGen Pharma Ltd.. UGN-103 is a synthetic, small molecule that targets the urothelial cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
UGN-103 TARGET	UGN-103	UroGen Pharma Ltd.	phase 3	Small molecule	Not publicly disclosed
CHS-0214	CHS-0214	Coherus Oncology, Inc.	phase 3	Bispecific T-cell engager (BiTE)	CD3 and tumor-associated antigen (specific target not publicly disclosed)
BMS-986353	BMS-986353	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	phase 3	CAR-T cell therapy	Tumor-associated antigen (specific target not publicly disclosed in detail)
KITE-753	KITE-753	Kite, A Gilead Company	phase 3	CAR-T cell therapy	Tumor-associated antigen (specific target not publicly disclosed in detail)
AK120	AK120	Akesobio Australia Pty Ltd	phase 3	Bispecific T cell engager	CD3 and tumor-associated antigen (specific target not publicly disclosed)
Placebo+AK111	Placebo+AK111	Akeso	phase 3	Bispecific T-cell engager (BiTE)	CD3 and tumor-associated antigen (specific target not publicly disclosed)
Pf-08052666	pf-08052666	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small molecule class)

Pfizer · 3 drugs in this class
Akorn, Inc. · 1 drug in this class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 drug in this class
Health Research, Inc. · 1 drug in this class
Imperial College London · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 drug in this class
Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
UroGen Pharma Ltd. · 1 drug in this class
Abivax S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). UGN-103 — Competitive Intelligence Brief. https://druglandscape.com/ci/ugn-103. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing